Navigation Links
Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
Date:9/17/2007

ous academic clinical research and results of use of the neo-bladder at Children's Hospital Boston were described in an article published in The Lancet on April 15, 2006.

The neo-bladder constructs for patients in both Phase 2 clinical trials are being developed at Tengion's state-of-the-art manufacturing facility using cells taken from a small biopsy of each patient's bladder. Each neo-bladder construct consists of a biodegradable scaffold seeded with cells cultured by Tengion scientists from the patient's own (i.e., autologous) healthy cells. A surgeon implants the neo-bladder construct in the patient's body, where it is designed to harness the body's inherent regenerative capabilities resulting in a regenerated bladder with improved functionality. The primary efficacy endpoint of the trial is urodynamic function of the neo-bladder at one year post-implantation. Data on the safety profile of the product will continue to be collected after the one-year endpoint measurement date. The trial is expected to complete enrollment over the next few months.

If the implanted neo-bladder constructs prove safe and effective, they have the potential to reduce the risks and complications associated with present means of treating failing bladders in adults with spinal cord injuries. The most common surgical procedure currently used to treat patients with failing bladders is known as enterocystoplasty, a procedure that was developed more than 100 years ago that uses the patient's own bowel tissue to augment the failing bladder. This procedure is associated with substantial and well-described side effects and risks.

"Bladder failure patients have not seen new treatment options in decades, and Tengion's technology has the potential to be a compelling advance," said Roger R. Dmochowski, M.D., professor with Vanderbilt University's Department of Urology. "We have been encouraged by results to date and look forward to the continued evaluation of the neo-bladder constr
'/>"/>

SOURCE Tengion, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
5. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
6. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
7. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
8. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
11. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014   Assurex Health, a ... to healthcare providers for behavioral health and chronic ... $30 million in equity financing from new and ... , President and Chief Executive Officer. ... development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... In response to urgent requests from the Deputy Minister ... Leone , Direct Relief delivered two 10-bed medical tents ... of local health workers who contract Ebola while fighting the ... center was constructed for foreign health care workers who may ... local Sierra Leonean health workers. With ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... Capital Partners, a leading private equity firm, today announced ... Executive Officer of Nycomed, as Healthcare Operating Executive.  Mr. ... Nycomed during Avista,s ownership of the company, which was ... 9.6 billion. Under Mr. Bjorklund,s leadership, Nycomed ...
... Biotechnology, Inc., a development stage biopharmaceutical company, today ... worldwide commercial rights to neratinib, a potent, irreversible ... the epidermal growth factor receptors, ErbB1 (EGFR), ErbB2 ... studied in the neoadjuvant, adjuvant and metastatic settings ...
Cached Medicine Technology:Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive 2Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive 3Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 2Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 3Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 4Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 5
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... has updated its blog to provide professional shopping tips on wedding ... at LunaDress.co.uk come with big discounts, up to 80 percent off. ... out to be a most exciting memory and can show off ... to a wedding. On the updated fashion blog, ladies can now ... big day . , Going out with friends to a party ...
(Date:12/25/2014)... 24, 2014 (HealthDay News) -- Among early stage breast ... than half of one percent will eventually develop leukemia ... reveals. The finding comes from a review of ... and 2007, and it suggests that the risk for ... experts had previously thought. "The frequency of bone ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 “ SmileStix ” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review and ... to create personal stickers. , The old saying goes, “A ... lot of words that can describe a single image, because ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... stress , , THURSDAY, Jan. 8 (HealthDay News) -- The most ... popular antiviral drug Tamiflu, but government health officials said Thursday ... the flu season so far has been slow, and that ... health officials adopting a watchful attitude for now. , While ...
... five action steps to improve responseWASHINGTON, Jan. 8 ... delivery of food and medical supplies to residents of ... access to food, clean water and medical help. U.S.-based ... this arrangement to allow sporadic delivery of aid as ...
... Tom Torlakson Introduces AB 89SACRAMENTO, Calif., Jan. 8 ... (LCA-CA), hailed California Assembly Member Tom Torlakson (D-11th ... providing funding for lung cancer research. For ... lung cancer research is being considered in the ...
... Factor in Decision for Florida Multi-Specialty Group ... Allscripts announced today that Physician Associates LLC, ... in the Southeast United States, has selected ... to automate and connect their 80 physicians ...
... St. Jude Children,s Research Hospital have demonstrated a ... They found that the antibiotics clindamycin and azithromycin, ... are more effective than a standard first-line treatment ... bacteria to lyse, or burst. , ...
... Healthcare,Solutions, Inc., formerly Allscripts Healthcare Solutions, Inc. (Allscripts ... the three and six,months ended November 30, 2008. ... ) , The Company,s ... November 30, 2008,include results from legacy Allscripts for ...
Cached Medicine News:Health News:Common Flu Strain Resistant to Popular Antiviral Drug 2Health News:Common Flu Strain Resistant to Popular Antiviral Drug 3Health News:Temporary Cease Fires Not Enough for Humanitarian Aid Groups Working in Gaza 2Health News:Temporary Cease Fires Not Enough for Humanitarian Aid Groups Working in Gaza 3Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13
... ultrasonic aspirator, portable unit ... aspirator for the fragmentation ... available only outside the ... a very compact design ...
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 7.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 7.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 8.0 mm and length 5 mm....
Medicine Products: